Potential Impacts of Alex Azar as Head of HHS

On Demand

  • 60 minutes

This event will explore the implications of President Trump‘s new Secretary of Health & Human Services (HHS), Alex Azar. which will have an important impact on HHS in general, and the FDA in particular. Azar’s potential impact on the future of the FDA, drug and device regulations, drug pricing and the drug approval process will be explored, as will Azar’s attitudes toward Medicaid and Medicare.

In this webinar expert speaker, Norma Skolnik will explore the implications of Alex being the new secretary of the HHS. This session will provide a background on Alex, President Trump’s new Head of the Department of HHS.

Session Highlights: 

  • Trump administration's Impacts on

  • 21st Century Care Act

  • Reins Act

  • Budget & Regulatory Cuts

  • Alex Azar’s history & background and statements made during his Confirmation hearing.

  • HHS Head Alex Azar and past policies that he has supported as well as his likely intentions for HHS programs.

  • Alex Azar's views and impacts on the following 

  • Opioid Epidemic 
  • ACA (Obamacare)
  • Feb 15 Budget Hearing
  • Drug Cost Issues 
  • Medicaid and Medicare

  • Scott Gottlob's role

Why You Should Attend:

This webinar will give you a brief overview of Alex Azar Background, Trump’s new Head of the Dept. of Health & Human Services. The presentation will cover what likely trends may be expected under his administration based on Azar’s background and statements made at his confirmation hearing. References to all relevant regulations and documentation will be provided.

Who Should Attend:

  • Regulatory Affairs managers

  • Directors & associates

  • Drug Safety managers

  • Compliance Specialists

  • Drug and Device managers

  • Medicare & Medicaid administrators

  • Marketing managers

  • Anyone involved in marketing Prescription drugs, Biologics and OTC drugs, medical devices, or supplements in the U.S. (Drug companies, Medical Device, Consumer Healthcare, Generic drug, and Biotech firms).

*You may ask your Question directly to our expert during the Q&A session.

** You can buy On-Demand and view it as per your convenience.

Norma Skolnik

Norma Skolnik

Norma Skolnik is currently a Regulatory Consultant with over 35 years of regulatory experience working with the pharmaceutical and dietary supplement industries. She was Director of Regulatory Affairs for the Americas for Cadbury Adams and Director of Regulatory Affairs for the Adams division of Pfizer before that. Prior to that she was Associate Director of Regulatory Affairs for the Warner-Lambert company and Associate Director Regulatory Affairs at American Home Products Whitehall-Robbins Division.

No Reviews Found

Want to attend in a Group? Call 844-810-1151 and Save upto 50%

Share this course with a friend

We Also Recommend

Food Safety and Pharmaceuticals

FDA :- Combination Products Regulations and Requirements

Pre Recorded
Feb 09, 2018 - Feb 16, 2018
Start Time:
08:00 AM (ET) | 05:00 AM (PT)
60 minutes

Food Safety and Pharmaceuticals

FDA FSMA Final Rule : Human and Animal Foods Preventive Control...

Sep 13, 2019 - Sep 20, 2019
Start Time:
08:00 AM (ET) | 05:00 AM (PT)
90 minutes


Get Notified about News, Webinars, Community & More